share_log

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18

HC Wainwright & Co.维持对Relay Therapeutics的买入评级,将目标股价下调至18美元。
Benzinga ·  07/17 06:22

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $20 to $18.

HC Wainwright & Co. 分析师罗伯特·伯恩斯维持Relay Therapeutics(纳斯达克股票代码:RLAY)的买入并将目标股价从20美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发